Scarica l'app Stockscreener
1.44
1.37%
-0.02
Pre-mercato:
1.43
-0.01
-0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.46
Aprire:
$1.47
Volume 24 ore:
6.02M
Relative Volume:
0.67
Capitalizzazione di mercato:
$432.12M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-0.96
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-4.00%
1M Prestazione:
+20.00%
6M Prestazione:
-17.48%
1 anno Prestazione:
-11.11%
Intervallo 1D:
$1.43
$1.53
Intervallo di 1 settimana:
$1.41
$1.53
Portata 52W:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.44 | 450.13M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.49 | 232.02B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.48 | 151.51B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
390.59 | 148.85B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.22 | 113.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.81 | 44.81B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Chromosome-level genome assembly with telomeric repeats at scaffold ends for Rhabdosargus sarba - Nature
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 29% Bounce - simplywall.st
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Pacific Biosciences Sees Stock Surge After Latest Product Launch - timothysykes.com
Pacific Biosciences Targets Profitability by 2027 With Record Consumables Revenue - Insider Monkey
Pacific Biosciences Sees Stock Volatility Amidst Mixed Financial Signals - StocksToTrade
Why PACB’s Stock is Rising? - StocksToTrade
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know - Nasdaq
Barclays Adjusts Price Target for PacBio (PACB) Amid Funding Con - GuruFocus
Third Generation Sequencing Market Set to Witness Significant - openPR.com
Long Read Sequencing Market Projected to Reach USD 6.98 - GlobeNewswire
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Transcript : Pacific Biosciences of California, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds - Yahoo Finance
Pacific Biosciences Approves Key Proposals at Annual Meeting - TipRanks
Powered by PacBio: Selected publications from May 2025 - PacBio
Pacific Biosciences Of California To Present At Jefferies Conference; Webcast At 8:45 AM ET - Nasdaq
Amgen To Present At Jefferies Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment - Yahoo Finance
Pacific Biosciences of California, Target ALS Collaborate for Genomic Study - marketscreener.com
PacBio (PACB) Joins Forces with Target ALS for Major Genomic Study | PACB Stock News - GuruFocus
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date - marketscreener.com
Pacific Biosciences of California: Sell Before Potential Reverse Split - Seeking Alpha
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacific Biosciences of California, Inc. (PACB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Media resourceS - PacBio
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy - sharewise
PureTarget repeat expansion and carrier panels enable high-throughput clinical research solutions - PacBio
PacBio to Present at Upcoming Investor Conferences - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - MSN
PacBio Stock Slips Despite New China Distribution Deal With Haorui - sharewise
PACB stock touches 52-week low at $0.94 amid market challenges - Investing.com Australia
PacBio (PACB) Expands Presence in China with New Distribution De - GuruFocus
PacBio (PACB) Expands Presence in China with New Distribution Deal | PACB Stock News - GuruFocus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene - Yahoo Finance
HiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms - PacBio
Pacific Biosciences: A Mountain Of Red Flags (NASDAQ:PACB) - Seeking Alpha
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences | PACB Stock News - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock News - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly Results | PACB Stock News - GuruFocus
PacBio clears allegations after special investigation By Investing.com - Investing.com Nigeria
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.69%
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):